1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tavotek Biotherapeutics (Hong Kong) Limited is currently managing 1 pending office action. This case is assigned to 1 distinct examiner, HUYNH, PHUONG N, who is responsible for the company's 1 pending office action. This concentration means that the immediate success of the company's patenting efforts is tied to the evaluation of a single individual within the patent office, requiring a focused prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701582 | ANTI-EGFR ANTIBODIES, ANTI-CMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF | HUYNH, PHUONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701582 | ANTI-EGFR ANTIBODIES, ANTI-CMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF | HUYNH, PHUONG N | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701582 | ANTI-EGFR ANTIBODIES, ANTI-CMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF | HUYNH, PHUONG N | — | §102§103§112 | Non-Final OA | — | Pending | Apr 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTavotek Biotherapeutics (Hong Kong) Limited has 1 pending office actions as of October 2026, spread across 0 art units and 1 examiners.
Phuong N Huynh has the most, with 1 of Tavotek Biotherapeutics (Hong Kong) Limited's pending office actions.
